In summary, 5-LOX inhibition by zileuton protects against cardiac hypertrophy, inflammation, and dysfunction in response to LV pressure overload by activating PPARα/NRF2 signaling in cardiomyocytes, which mediates oxidation balance. Here, PPARA is linked to cardiac hypertrophy.